New Entities (NE Program)
 The
biological revolution has created new horizons in healthcare.
With new technologies, genomics and proteomics, the mainstream
academic R&D efforts have result in the discovery of new
targets. Thanks to its extensive academic network and its
close relationships with more than 100 researchers at French
scientific institutions, BioAlliance is well positioned to
select the most interesting targets in the drug resistance
field in order to develop new drugs targeting large markets.
New drugs against new targets are another way to overcome
resistance while opening opportunities for corporate partnering
with large pharmaceutical and biotechnology companies. There
is considerable interest within the pharmaceutical industry
in acquiiring new drugs, including especially those that overcome
resistance issues in HIV and cancer treatment, benefiting
fromintracellular targeting or bioavailability
improvement.
|
